Vimarsana
Biggest News Aggregation in the World

Page 41 - Drug Controller General News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Drug Controller General. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Drug Controller General Today - Breaking & Trending Today

Drug Controller clamps down on e-pharmacies, to meet this month to formulate regulations - Vimarsana News

Drug Controller clamps down on e-pharmacies, to meet this month to formulate regulations

On Friday, the Drug Controller General of India (DCGI) had issued a show cause notice to e-pharmacies over purported violations of the provisions of the Drugs and Cosmetics Act

DCGI Sends Notices To Tata 1mg, Amazon, 18 Other Epharmacies For Violating Rules - Vimarsana News

DCGI Sends Notices To Tata 1mg, Amazon, 18 Other Epharmacies For Violating Rules

The Drug Controller General of India (DCGI) has sent show-cause notices to 20 epharmacies, including Tata 1mg, Amazon, and Flipkart

Source: inc42.com
Celebrating Rare Disease Day and 40 Years of the Orphan Drug Act Advocating for Rare Disease Patients and Their Families - Vimarsana News

Celebrating Rare Disease Day and 40 Years of the Orphan Drug Act Advocating for Rare Disease Patients and Their Families

Herndon, VA (PRWEB) February 07, 2023 -- Global life expectancy has more than doubled over the last two centuries, from less than 30 years to more than 72

Source: prweb.com
Another Digital Vision syrup fails retest - Vimarsana News

Another Digital Vision syrup fails retest

An Ambala court has revealed that the third sample of the syrup manufactured by Digital Vision, which is suspected to be behind the death of 12 children in J&K’s Udhampur in 2020, also failed the quality test on retesting.

Alzheimer's Disease: Experts discuss impacts, benefits and drawbacks of new drug - Vimarsana News

Alzheimer's Disease: Experts discuss impacts, benefits and drawbacks of new drug

Trial studies on Lecanemab, a new investigational drug for the treatment of Alzheimer’s Disease, have shown it to moderately slow down cognitive and functional decline among early-stage patients. Doctors help decode the impact, benefits and possible drawbacks